MAXCYTE INC. - COMMON STOCK

MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform

04 May 2023 07:05:53 By Nasdaq GlobeNewswire

MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023

12 Apr 2023 15:05:30 By Nasdaq GlobeNewswire

MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

27 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results

15 Mar 2023 15:05:23 By Nasdaq GlobeNewswire

MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology

08 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance

06 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences

01 Feb 2023 15:05:53 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

03 Jan 2023 15:05:00 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases

05 Dec 2022 01:00:00 By Nasdaq GlobeNewswire

MaxCyte Reports Third Quarter 2022 Financial Results

09 Nov 2022 15:05:03 By Nasdaq GlobeNewswire

MaxCyte to Participate in Upcoming Investor Conferences

02 Nov 2022 07:05:00 By Nasdaq GlobeNewswire

MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022

12 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program

28 Sep 2022 07:05:00 By Nasdaq GlobeNewswire

MaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 Biotech Corridor

21 Sep 2022 07:05:00 By Nasdaq GlobeNewswire

MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

07 Sep 2022 15:05:00 By Nasdaq GlobeNewswire

MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results

10 Aug 2022 15:05:01 By Nasdaq GlobeNewswire

MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022

15 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs

12 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 May 2022 15:30:00 By Nasdaq GlobeNewswire

MaxCyte Reports First Quarter Financial Results

09 May 2022 15:05:03 By Nasdaq GlobeNewswire